Maternal care for anti-D [Rh] antibodies, first trimester (fetus 3)
ICD-10 O36.0113 is a billable code used to indicate a diagnosis of maternal care for anti-d [rh] antibodies, first trimester (fetus 3).
O36.0113 refers to maternal care for a pregnant woman who has developed anti-D (Rh) antibodies during the first trimester of her pregnancy with her third fetus. This condition arises when an Rh-negative mother is exposed to Rh-positive blood, typically from a previous pregnancy or transfusion, leading to the production of antibodies that can cross the placenta and affect the fetus. The presence of these antibodies can lead to complications such as hemolytic disease of the newborn, fetal growth restriction, and fetal distress. Close monitoring and management are essential to mitigate risks, including regular ultrasound assessments to evaluate fetal growth and well-being, as well as potential interventions like intrauterine transfusions or early delivery if fetal distress is detected. Maternal care in this context involves a multidisciplinary approach, including obstetricians and maternal-fetal medicine specialists, to ensure both maternal and fetal health are prioritized throughout the pregnancy.
Detailed records of maternal antibody testing, fetal monitoring, and any interventions performed.
Management of Rh sensitization, monitoring for fetal growth restriction, and addressing fetal distress.
Accurate coding requires thorough documentation of maternal history and ongoing assessments of fetal health.
Comprehensive documentation of high-risk assessments, including ultrasound findings and laboratory results.
Management of pregnancies complicated by Rh incompatibility, including potential transfusions or early delivery.
Special attention to the coordination of care among specialists and the need for detailed follow-up.
Used for monitoring fetal growth in pregnancies complicated by anti-D antibodies.
Document the reason for the ultrasound and findings related to fetal growth.
Obstetricians should ensure that ultrasound findings are clearly linked to the diagnosis of anti-D antibodies.
Accurate coding of O36.0113 is crucial for ensuring appropriate care management for the mother and fetus, as it reflects the complexity of the pregnancy and the need for specialized monitoring and interventions.